Get Live Data

Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses
Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licensesView Video

Latest Share Chat

  2. Share Prices
  3. ARIX.L Share Price
  4. ARIX.L Share Regulatory News

Pin to quick picksARIX.L Regulatory News (ARIX)

ARIX.L Information
  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

12345678910
Date   Source Headline
7th Feb 202411:30 amEQSTransaction Update
29th Jan 202412:15 pmEQSResults of First General Meeting
24th Jan 20245:30 pmEQSHolding(s) in Company
24th Jan 20245:30 pmEQSHolding(s) in Company
23rd Jan 20247:00 amEQSUpdate on the Scheme and Publication of Notice of Second General Meeting
22nd Jan 20247:00 amEQSUpdate on the Scheme and Resignation of Directors
19th Jan 20247:01 amEQSFinancial update on Harpoon Therapeutics acquisition by Merck (MSD)
19th Jan 20247:00 amEQSUnaudited NAV for December 2023
8th Jan 20245:15 pmEQSPortfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
5th Jan 20247:00 amEQSPublication of Circular and RTW Bio Prospectus
4th Jan 20245:30 pmEQSHolding(s) in Company
22nd Dec 202311:00 amEQSUpdate regarding timing of Proposed Scheme of Reconstruction
13th Dec 20237:00 amEQSUnaudited NAV for November 2023
8th Dec 20237:00 amEQSPortfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
13th Nov 20234:00 pmEQSCorrection: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
10th Nov 20238:00 amEQSPortfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
10th Nov 20237:00 amEQSPDMR Notification & Director Shareholding
8th Nov 20237:05 amEQSUnaudited NAV for October 2023
3rd Nov 20234:30 pmEQSPDMR Notification & Director Shareholding
2nd Nov 20236:20 pmEQSPDMR Notification & Director Shareholding
1st Nov 20234:30 pmEQSPortfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
1st Nov 20237:06 amRNSRTW Biotech to acquire Arix Bioscience's assets
24th Oct 20237:00 amEQSPortfolio company Harpoon Therapeutics announces up to $150 million private placement
6th Oct 20237:00 amEQSUnaudited NAV for September 2023
27th Sep 20237:01 amEQSInterim Results for the Six Months Ended 30 June 2023
27th Sep 20237:00 amEQSBoard Change
14th Sep 20237:01 amEQSNotice of Results and Investor Presentation
14th Sep 20237:00 amEQSUnaudited NAV for August 2023
7th Aug 20237:00 amEQSUnaudited NAV for July 2023
17th Jul 20233:00 pmEQSHolding(s) in Company
13th Jul 20237:01 amEQSArix Announces Strategic Review
13th Jul 20237:00 amEQSUnaudited NAV for June 2023
23rd Jun 20232:04 pmEQSPortfolio company Disc Medicine raises $157.8 million in public offering
9th Jun 20232:53 pmEQSPortfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
9th Jun 20237:00 amEQSUnaudited NAV for May 2023
31st May 202311:51 amRNSDirector/PDMR Shareholding
24th May 20237:00 amEQSCorrection: Result of Annual General Meeting
23rd May 20234:30 pmEQSResult of Annual General Meeting
16th May 20234:36 pmEQSPortfolio company Ensoma announces closing of Series B Extension
12th May 20237:00 amEQSUnaudited NAV for April 2023
5th May 20234:30 pmRNSTotal Voting Rights
4th May 20235:02 pmRNSDirector/PDMR Shareholding
4th May 202312:15 pmRNSDirector/PDMR Shareholding
2nd May 20233:52 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amEQSArix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
25th Apr 20237:03 amEQSFinancial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
19th Apr 20231:30 pmEQSFull Year results now to be released on 25 April 2023
17th Apr 20237:00 amEQSUnaudited NAV for March 2023
14th Apr 202312:00 pmEQSNotice of Results and Investor Presentation
28th Mar 20237:00 amEQSPortfolio company Harpoon Therapeutics announces closing of $25 million private placement
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.